Advanced Enzyme PAT Surges 69% to ₹453 Mn in Q4

Advanced Enzyme Technologies Limited has filed the transcript of its earnings conference call held on May 12, 2026, with the stock exchanges. The call discussed the audited financial results for the quarter and year ended March 31, 2026. The audio recording is available on the company's website.

Consolidated Financial Performance

The company reported its highest-ever quarterly and annual revenue for the fiscal year ended March 2026. Revenue from operations for Q4 FY26 stood at ₹2,034 million, a growth of 22% year-on-year and 18% sequentially. For the full year FY26, revenue increased by 17% to ₹7,458 million.

Profitability metrics showed significant improvement. Profit after tax (PAT) for Q4 FY26 surged 69% year-on-year to ₹453 million, compared to ₹260 million in the corresponding quarter of the previous year. For the full year, PAT grew by 30% to ₹1,736 million. EBITDA for the quarter stood at ₹632 million, up 39% year-on-year, with margins remaining strong at 31%.

Metric (₹ Mn)	Q4 FY26	Q4 FY25	Change (YoY %)	FY26	FY25	Change (%)
Revenue	2,034	1,672	+22%	7,458	6,369	+17%
EBITDA	632	456	+39%	2,291	1,944	+18%
PAT	453	260	+69%	1,736	1,340	+30%
EBITDA Margin (%)	31%	27%	—	31%	31%	—
PAT Margin (%)	22%	16%	—	23%	21%	—

Segmental and Geographical Highlights

All four business segments delivered year-on-year growth. The Human Healthcare segment remained the largest contributor, accounting for 63% of total revenue with a 24% increase to ₹1,281 million. Animal Healthcare revenue grew 19% to ₹250 million, while Bio-Processing increased by 17% to ₹324 million. The Specialized Manufacturing segment grew 17% to ₹180 million.

Domestic sales accounted for 52% of total revenue in Q4 FY26, rising 51% year-on-year to ₹1,061 million. International sales stood at ₹973 million, with Asia (ex-India) recording 38% growth and the rest of the world reporting 44% growth.

Operational Updates

The company filed two food enzyme dossiers with the European Food Safety Authority (EFSA) and three with the US FDA during the year. Management anticipates approval for anti-inflammatory products filed in the European region during the current fiscal year. The new R&D center in Nashik is expected to become fully operational in the latter half of FY27.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.34%	-3.77%	+24.31%	+18.03%	+28.95%	-22.24%

Advanced Enzyme Technologies announced its audited financial results for the fourth quarter and financial year ended March 31, 2026, reporting a robust consolidated performance. Net profit for FY26 rose 30% to ₹1,736 million compared to ₹1,340 million in the previous year, while revenue from operations increased by 17% to ₹7,458 million from ₹6,369 million in FY25. The board recommended a final dividend of ₹1.35 per equity share for the financial year ended March 31, 2026, subject to shareholder approval. Alongside the results, the company shared its strategic growth plans for FY27, focusing on B2C expansion and geographic diversification.

Consolidated Financial Performance

For the fourth quarter of FY26, revenue from operations grew by 22% year-on-year to ₹2,034 million, up from ₹1,672 million in Q4 FY25. Net profit for the quarter surged by 69% to ₹453 million from ₹267 million in the corresponding period of the previous year. EBITDA for Q4 FY26 stood at ₹632 million, a 39% increase from ₹456 million in Q4 FY25, with the EBITDA margin expanding to 31% from 27%. The following table summarises the key consolidated financial metrics for the quarter and full year:

Metric (₹ mn):	Q4 FY26	Q4 FY25	FY26	FY25
Revenue from Operations	2,034	1,672	7,458	6,369
EBITDA	632	456	2,291	1,944
Profit Before Tax	598	435	2,325	1,874
Net Profit	453	267	1,736	1,340
Basic EPS (₹)	3.84	2.37	15.08	11.72

Segment and Geographical Performance

The Human Nutrition segment was the primary growth driver, contributing 63% to total revenue in Q4 FY26. It grew by 24% year-on-year to ₹1,281 million, driven by increased activities in the Pharma/API and Bio-catalysis businesses. For the full year FY26, the segment grew by 15% to ₹4,674 million. The Animal Nutrition segment grew by 19% in Q4 FY26 to ₹250 million and by 25% for the full year to ₹946 million. The Bio-Processing segment reported a 17% growth in Q4 FY26 to ₹324 million, while the Specialized Manufacturing segment grew by 17% to ₹180 million.

Geographically, India remained the largest market, contributing 52% to Q4 FY26 revenue with ₹1,061 million, representing a 51% year-on-year growth. Domestic sales accounted for 50% of the total revenue for FY26. International sales stood at ₹973 million in Q4 FY26, with the Americas and Europe seeing declines of 11% and 7% respectively, while Asia (ex-India) grew by 38%.

FY27 Growth Strategy and Operational Highlights

Advanced Enzyme Technologies has outlined a focused growth strategy for FY27 centred on expanding its B2C presence and strengthening its international sales infrastructure. The company launched its own nutraceutical brand, Wellfa, in India to drive B2C growth within the Human Nutrition segment. In the Animal Nutrition segment, the company plans to expand its sales team across the USA, MENA, and Asian regions to capture a larger share of international markets. The company is also conducting trials to develop new Animal Nutrition products and noted progress in Bio Catalysis for API manufacturers, with several products in advanced plant-level trials. Additionally, Advanced Enzyme Technologies remains committed to exploring strategic inorganic acquisition opportunities to enhance its global footprint.